<SEC-DOCUMENT>0001213900-15-005621.txt : 20150817
<SEC-HEADER>0001213900-15-005621.hdr.sgml : 20150817
<ACCEPTANCE-DATETIME>20150803080616
ACCESSION NUMBER:		0001213900-15-005621
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150729
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150803
DATE AS OF CHANGE:		20150803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		151021075

	BUSINESS ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-300-2131

	MAIL ADDRESS:	
		STREET 1:		546 5TH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k072915_actiniumpharmac.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
July 29, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>ACTINIUM PHARMACEUTICALS,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>000-52446</B></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>74-2963609</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction<BR>
of incorporation)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(IRS Employer<BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 54%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>757 Third Avenue, 21<SUP>st</SUP> Floor</B><BR>
<B>New York, NY</B></TD>
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>10017</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(646) 459-4201</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>546 Fifth Avenue, 14<SUP>th</SUP> Floor, NY, NY 10036</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Former name or former address, if changed since last report)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 2.02.</B></FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a letter to shareholders, dated July 29,
2015, Actinium Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) reported that <FONT STYLE="color: #282726; background-color: white">its
pro forma cash position at June 30, 2015 was approximately $27 million.</FONT> A copy of the shareholder letter is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item&nbsp;2.02 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 7.01.</B></FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A copy of a shareholder letter mailed to Company
shareholders on July 29, 2015 is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item&nbsp;7.01
by reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein is deemed to be &quot;furnished&quot;
and shall not be deemed to be &quot;filed&quot; for purposes of the Securities Exchange Act of 1934, as amended. The information
set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information
in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The response to Item&nbsp;2.02 is incorporated
herein by reference to this Item&nbsp;7.01.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Item 9.01.</B></FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and
Exhibits </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">(d) Exhibits.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><B>Exhibit </B><BR>
<B>Number</B></TD>
    <TD STYLE="width: 1%; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 91%; border-bottom: Black 1.5pt solid; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">99.1</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Letter to Shareholders, dated July 29, 2015</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>ACTINIUM PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-bottom: 1.5pt">Dated: August 3, 2015</TD>
    <TD STYLE="padding-bottom: 1.5pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ Kaushik J. Dave&#9;</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Kaushik J. Dave</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">3</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k072915ex99i_actinium.htm
<DESCRIPTION>LETTER TO SHAREHOLDERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="color: #222222; font: bold 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: white">&nbsp;<IMG SRC="img001.jpg" ALT=""></P>

<P STYLE="color: #222222; font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="color: #222222; font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">Letter
to Shareholders</P>

<P STYLE="color: #222222; font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="color: #222222; font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">July
29, 2015</P>

<P STYLE="color: #222222; font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="color: #222222; font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-weight: normal">Dear
Fellow Shareholders,</FONT></P>

<P STYLE="color: #222222; font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222">So far in 2015, Actinium
has made many strides to advance our drug candidates, Actimab-A and Iomab-B, in their clinical development and towards eventual
commercial launch. I want to summarize for you our many accomplishments in 2015 thus far:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><B><I><U>Key
2015 Achievements To-Date</U></I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed a provisional patent application
for Infusion Administration of Iomab-B on June 24, 2015, enhancing the Company&rsquo;s already extensive patent portfolio</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Closed a $20 million financing in February
and a $5 million financing in June that together greatly strengthened our balance sheet</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presented clinical data at the 2015 ASCO
Annual Meeting that generated significant interest from the scientific community, which is helping the Actimab-A trial</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hosted a Key Opinion Leader event on May
12, 2015, focused on the potential role of Iomab-B in bone marrow transplants, further showcasing the strong support we enjoy from
thought leaders</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Formulated a partnership with a leading
non-profit health organization, Aplastic Anemia &amp; MDS International Foundation, on April 22, 2015, to present educational forums
to patients and their families </FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Began dosing patients in the final Cohort
4 of the Actimab-A Phase 1 trial, following new Cohort 3 data that demonstrated the strong anti-leukemic effect, with no dose limiting
toxicities observed</FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Continued to
build our team, deepening our R&amp;D capabilities </FONT></TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Requested a pre-IND
meeting with the U.S. Food and Drug Administration</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; background-color: white; color: #222222"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #222222"><B><I><U>Rising
Profile Within Science Community, </U></I></B></FONT><B><I><U>Growing Team of World-Class Professionals</U></I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">Actinium&rsquo;s
profile within the scientific community continues to grow, as demonstrated by the review of the initial patient outcomes from the
ongoing Actimab-A Phase 1/2 clinical trials by oncology experts at the 2015 ASCO (American Society of Clinical Oncology) annual
meeting on May 31, 2015, the Company&rsquo;s sponsorship of the 9th Symposium on Targeted Alpha Therapy in Poland on May 19-21
and a Key Opinion Leaders event we hosted in New York in May of 2015.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify; background-color: white; color: #222222">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222">Moreover, Actinium has
enhanced its team, as evidenced by the addition of Jeng-Dar Yang, Ph.D., as Vice President of Pharmaceutical Development on May
13, 2015, and the earlier appointment of Dr. Roland Turck, MD, former President, Global Specialty Medicine, Bayer Healthcare, as
Senior Board Advisor in February of 2015. These additions demonstrate the Company's commitment to building a team of experts that
will enhance and accelerate the development, commercialization, and licensing potential of our highly differentiated clinical assets.
Our ability to attract the highest caliber senior executives, each with more than 20 years of experience and prior success in the
healthcare industry, also speaks to the potential of our technology platform and core Iomab-B and Actimab-A programs. This growing
team of manufacturing and business executives strengthens our R&amp;D and managerial capabilities, which, in turn, we believe will
play a key role in ensuring that we begin to meet or exceed our goals going forward. We plan on adding selectively to the core
leadership team as we build out our clinical development organization in anticipation of the upcoming Phase 2 trial for Actimab-A
and the Phase 3 trial for Iomab-B.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I><U>Strengthening Our Balance Sheet</U></I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: #222222">On the
financial front,</FONT><FONT STYLE="color: #282726; background-color: white"> in February 2015, </FONT><FONT STYLE="color: #222222">we
</FONT><FONT STYLE="color: #282726; background-color: white">strengthened our balance sheet with an offering of common shares and
warrants that raised $20 million. Subsequently, we raised an additional $5 million in an equity issuance in June 2015 and our pro
forma cash position at June 30<SUP>th</SUP> 2015 was approximately $27 million. We believe that we are now well positioned to maintain
our research activities and enable the transformation of our company from a clinical trial perspective. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #282726"><FONT STYLE="background-color: white"><B><I><U>Meeting
Challenges Quickly and Efficiently</U></I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">While
marked by significant success, 2015 has not been without its challenges. We would be the first to acknowledge that progress has
been slower than anticipated and has not come without unforeseen challenges.&nbsp;I want to update you on how we have handled some
of the hurdles we have encountered and on our plans to move forward.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">We
had originally expected interim Phase 2 data for Actimab-A to be available by ASH 2015 (American Society of Hematology), the event
sponsored by the preeminent scientific society for blood cancer research, this coming December. That timeline appears unlikely
at this point, as the completion of Phase 1 has taken longer than we initially anticipated, primarily reflecting slower than expected
enrollments. We have since resolved this problem and are benefitting from renewed interest in the program from investigators due
to the results in the third cohort.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="color: #222222">We
successfully completed the third cohort of AML (Acute Myeloid Leukemia) patients in our Phase 1/2 trial for Actimab-A in early
2015. </FONT>In Cohort 3, patients received two doses of Actimab-A at 1.5 &mu;Ci/kg per dose compared to a lower dose of 1.0 &mu;Ci/kg
that patients received in Cohort 2. Two out of three Actimab-A treated patients achieved complete remission in Cohort 3, with different
degrees of hematological recovery (CRi). By comparison, in Cohort 2, one patient achieved CRi.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">Given
the improved results we recorded at higher dosages of Actimab-A in Cohort 3, we were extremely optimistic as we began the enrollment
process for Cohort 4 in March of this year. However, research staff turnover at two sites rendered them inactive for a period of
time, which constrained the enrollment we needed to move on to Phase 2. We are in the process of activating more centers to facilitate
patient enrollment. Baylor&rsquo;s Charles A. Sammons Cancer Center, one of the largest oncology centers in the nation, treating
over 55,000 cancer patients every year, and other top US cancer centers including the Memorial Sloan Kettering Cancer Center, the
MD Anderson Cancer Center, the Fred Hutchinson Cancer Research Center, Johns Hopkins Medicine and the University of Pennsylvania
Health System are among the clinical trial sites that support the ongoing enrollment in our Phase 1/2 study. We also expect to
have Columbia University fully functioning as a trial site in the near future, having met their internal requirements. This is
very important, as our principal investigator Dr. Joseph Jurcic is the Head of their Division of Hematological Malignancies. Moreover,
with encouraging results observed as Phase 1 progresses, we anticipate strong support from this network as we enroll patients for
Phase 2.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">Regarding
Iomab-B, we had initially anticipated that the Phase 3 trial would commence in the first half of 2015. Unfortunately, we encountered
an unexpected manufacturing problem with scale-up &ndash; manufacturing in large quantities &ndash; that pushed the timeline back.
Iomab-B is a biological product, which, as the name suggests, means that it is manufactured from biological sources that have a
relatively short shelf life. As a result, the manufacturing scale-up can be challenging, especially for certain types of cell lines.
Further complicating the issue was the significant (5X) difference in batch size required for Phase 3 versus Phase 2. The clinical
batches for Phase 3 are manufactured in 500 liter bioreactors compared to the smaller liter bioreactors used to manufacture product
for the Phase 1/2 trials. I am pleased to report that this issue has been resolved and that we have a process that can scale for
commercial production. Moreover, we have also greatly increased our oversight of the manufacturing process and of the contractor.
Further, we have generated valuable intellectual property, know-how and trade secrets that will further protect the Iomab-B process
now at commercial scale. We are now moving ahead quickly to make up for lost time</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><B><I><U>Moving
Iomab-B and Actimab-A Forward is Our Priority</U></I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">With the Iomab-B manufacturing issue
behind us, we are now in a position to produce sufficient quantities or batches of Iomab-B to make us eligible to move forward
with the U.S. Food and Drug Administration (FDA). As many of you are aware, during the early development of a new drug, we are
required to apply for and obtain the&nbsp;Investigational New Drug (IND) designation from the FDA. Earlier this month, we submitted
a request for a pre-IND meeting for Iomab-B. Typically, the FDA will respond to a meeting request within 60 days of receiving an
application. We have obtained a response consistent with that timeline and are optimistic that we will move through the meeting
and application process successfully and obtain approval from the FDA that will allow us to move into the critical Phase 3 phase
for Iomab-B.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">As
we begin the IND application process for Iomab-B and progress through Cohort 4 of Actimab-A patients, we have ramped up our business
development efforts, with an eye towards finding suitable partners for both products to support their development and future commercial
launch. We are in discussions with a number of large pharmaceutical companies. Although it is still early in this process, we are
encouraged by the conversations underway, as feedback has been positive. We are also actively pursuing potential licensing opportunities
for both products and our platform technology to support further clinical development across multiple indications in cancer. We
continue to explore all options actively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="color: #282726; background-color: white">Our
chief goal is to bring Iomab-B to market across multiple indications and to establish the clinical validity of Actimab-A for the
treatment of AML in the near-term. We would like to realize these goals sooner rather than later, but we will not compromise on
quality as we seek to build an advanced, world-class oncology company that can address the challenges of many types of cancers.
We are confident that our technologies can provide us with many potentially first-in-class drugs to address unmet medical needs.
</FONT><FONT STYLE="color: #222222"> </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #282726"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #282726"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="color: #222222">If
there was one good thing that came out of the issues we have encountered in recent months, it is that we feel we are now better
equipped to deal with other enrollment or manufacturing problems that might arise in the future. </FONT><FONT STYLE="color: #282726; background-color: white">Our
entire team is now more experienced, stronger and completely focused on meeting our corporate objectives. We also understand the
need to, whenever possible, make up for the time that we&rsquo;ve lost. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #282726"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="background-color: white">As
the Actinium story improves, we will step up our investor relations efforts with road shows and institutional and retail outreach
programs. We plan to manage an active communications campaign for the purpose of increasing our exposure within the investment
community, including potentially hosting an Investor Day down the road. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #282726"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="color: #222222">We
wish to thank you, our shareholders, for your continued support. Given the significant medical need potentially addressed by Iomab-B
for bone marrow transplants and Actimab-A initially in newly diagnosed secondary AML patients. </FONT><FONT STYLE="color: #282726; background-color: white">We
believe that we are on the verge of transformation from a clinical program perspective and that within twelve months the company
will have Actimab-A in a Phase 2 trial and Iomab-B in a Phase 3 trial. </FONT><FONT STYLE="color: #222222">We remain confident
about the potential value of both products as we advance both programs closer to commercialization.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">We
look forward to updating you on our continued progress.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">Sincerely,</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">Kaushik
J. Dave, President and CEO</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222"><B><I>Forward-Looking
Statement for Actinium Pharmaceuticals, Inc.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #222222">This
news release contains &quot;forward-looking statements.&quot; These statements are based on management's current expectations and
involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The
forward-looking statements may include statements regarding product development, product potential, or financial performance.&nbsp;No
forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals
undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events,
or otherwise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center; background-color: white">4</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 ($# 2(  A$! Q$!_\0
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M9S+XK^)/B;Q3<+H/AKXC:UX8ACUJ3P$FK7DD%O'X2T6PA75_B1JRS>39:/\
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MRCB<KX1RB-;*_#_A.=6U+(N'U4:CB\52H2^H5<]SV5*&8YSB\-15&G.6'RG
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MI")X7UR?^RI=/O=#_7+_ ():_LO?L\_L:_LLZ'^SW^S/\;X?C_\ #KPIXO\
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M(=0TK5]*U"U>2VOM.U&QN(+NSNX'>&>WFCDC9D8$[59@%%%% !1110 4444
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M?$_XC>,]35K[6_$.IZWXS\9^)]8O90B+/>WLNHZSK%_<S.L<,9>>:1BD<:]
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MT_6-1U#2?#;-H5G:37'[,T8 Z#%%?YD'W(4444 %%%% !1110 4444 %%%%
M!1110 4A (P0"/0C(]?YT44-)Z-)I[IZI^J=T_N :T43 !HXV 96 9%(#(P=
M&&1]Y' =3U5@&&" :<%4<!0!UP !SZ\444>73?YWO?UOK?>^M[ZAW?5[OJ_5
..[OYMBT444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
